SYDNEY, AUSTRALIA--(Marketwired - Jun 23, 2014) - Prima BioMed Ltd (
The research paper relates to the Company's CAN-002 clinical trial of CVac in 28 patients with advanced epithelial ovarian cancer, completed in 2007. The clinical activity of CVac in ovarian cancer was evident from the CAN-002 data, based on decline or stabilization of CA125 in some patients. CVac was well tolerated by patients. The CAN-002 trial supported the continued clinical development of CVac.
A full copy of the research article is available on the Journal for ImmunoTherapy of Cancer website: http://www.immunotherapyofcancer.org/content/2/1/16/abstract.
About Prima BioMed Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
For further information please contact: USA Investor/Media: Adam Holdsworth ProActive Capital +1 (646) 862 4607 Email Contact Australia Investor/Media: Mr Matthew Gregorowski Citadel Communications +61 (0) 422 534 755 Email Contact Europe Investor/Media: Mr. Axel Muhlhaus edicto GmbH +49 (0) 69 905505-52 Email Contact
